Alliance for Clinical Trials in Oncology

Huntsman Cancer Institute joins myeloMATCH, a National Cancer Institute-sponsored program matching AML/MDS patients with trials based on genetic signatures, aiming to advance precision medicine. Patients undergo bone marrow biopsy for diagnosis and are assigned trials based on disease type and response to therapy, using groundbreaking technology to detect measurable residual disease (MRD).

Huntsman Cancer Institute joins an innovative clinical trials program, myeloMATCH, to match AML and MDS patients with trials based on their genetic signature, aiming to improve precision medicine and personalized cancer care.

Pfizer and AFT announced phase 3 PATINA trial results showing Ibrance plus standard-of-care improved progression-free survival in HR+, HER2+ metastatic breast cancer. Median PFS was 44.3 months with Ibrance vs. 29.1 months without, extending PFS by over 15 months. Safety profile consistent with known data. Results presented at SABCS.

The PROSPECT-Lung trial, led by Dr. Raid Aljumaily, evaluates timing of immunotherapy for operable non-small cell lung cancer. It aims to determine which approach—chemotherapy and immunotherapy before surgery or surgery followed by chemotherapy and immunotherapy—yields better outcomes. The trial, part of the National Cancer Institute’s Clinical Trials Innovation Unit, seeks to generate real-world applicable findings and streamline clinical trial processes.

The PROSPECT-Lung trial, a large multicenter study, aims to evaluate the role of immunotherapy before and after surgery in resectable non-small cell lung cancer, determining if it improves survival and cancer-free status. It seeks to answer whether perioperative immunotherapy is more effective than adjuvant therapy alone. The trial is part of the NCI's Clinical Trials Innovation Unit, aiming to simplify trials and improve their efficacy.

Exelixis announced the US FDA will discuss the sNDA for cabozantinib (Cabometyx) for treating advanced pancreatic and extra-pancreatic neuroendocrine tumours at a March 2025 ODAC meeting. The sNDA is based on the phase 3 CABINET trial results, showing cabozantinib's significant improvement in progression-free survival compared to placebo. Cabometyx is approved for various cancers and has received regulatory approvals in over 65 countries.

Adding veliparib to temozolomide did not improve overall survival in newly diagnosed glioblastoma patients with MGMT promoter hypermethylation, according to a phase II/III trial reported in JAMA Oncology.

A phase 2/3 study (NCT03701308) found that combining uproleselan with 7+3 chemotherapy did not significantly improve event-free survival (EFS) for older patients with newly diagnosed AML compared to chemotherapy alone. The trial, enrolling patients aged 60 and older, did not meet its primary EFS endpoint in phase 2. The National Cancer Institute and the Alliance for Clinical Trials in Oncology plan to analyze subgroup efficacy for potential further research. Earlier phase 3 trial results showed a modest overall survival benefit with uproleselan in relapsed or refractory AML patients.

Combining uproleselan with 7+3 chemotherapy did not significantly improve event-free survival (EFS) in older patients with newly diagnosed AML eligible for intensive chemotherapy, according to a phase 2/3 study (NCT03701308). The study's primary endpoint of EFS was not met, and further subgroup analysis is ongoing to identify potential efficacy signals. Topline data from the trial will be presented at a future medical meeting.

GLP-1 drugs face obstacles like high prices and limited insurance coverage, but changes are expected in the next five years. Semaglutide improved kidney function in overweight or obese patients with albuminuric chronic kidney disease without diabetes. Glycomimetics stock surged on acquisition news, while its leukemia drug study failed. Coya's Alzheimer's drug showed promise with less frequent dosing but led to stock decline with more frequent dosing. Lexicon seeks FDA approval for Zynquista, an oral adjunct to insulin for type 1 diabetes. Astellas withdrew its EU MAA for geographic atrophy treatment.